Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -265.64% is 42% above its 5-year average of -455.30%, near the high end of its 5-year range (-64051.22%–-54.78%).
7.32% above its 12-month average of -286.63%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -54.78%.
OPERATING MARGIN
-265.64%
OPERATING MARGIN AVG TTM
-286.63%
OPERATING MARGIN AVG 3Y
-386.19%
OPERATING MARGIN AVG 5Y
-455.30%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+7.32%
CURRENT VS 3Y AVG
+31.22%
CURRENT VS 5Y AVG
+41.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Foghorn Therapeutics Inc.
Market Cap
$117.43M
Operating Margin
-265.64%
TTM Avg
-286.63%
3Y Avg
-386.19%
5Y Avg
-455.30%
Market Cap
$118.02M
Operating Margin
-1220.49%
TTM Avg
-1443.83%
3Y Avg
-998.11%
5Y Avg
-830.42%
Market Cap
$116.59M
Operating Margin
-415175.00%
TTM Avg
-405687.50%
3Y Avg
-206404.23%
5Y Avg
-137602.82%
Market Cap
$118.50M
Operating Margin
-754.08%
TTM Avg
-1999.61%
3Y Avg
-1887.55%
5Y Avg
-2072.97%
Market Cap
$118.63M
Operating Margin
-33.18%
TTM Avg
-17.71%
3Y Avg
-9.45%
5Y Avg
-4.00%
Market Cap
$119.09M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$114.24M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$113.77M
Operating Margin
-255.05%
TTM Avg
-370.20%
3Y Avg
-218.02%
5Y Avg
-145.34%
Market Cap
$111.17M
Operating Margin
28.39%
TTM Avg
14.20%
3Y Avg
7.10%
5Y Avg
4.73%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $117.43M | -265.64% | -286.63% | -386.19% | -455.30% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -1220.49% | -1443.83% | -998.11% | -830.42% |
| Genelux Corporation (GNLX)vs › | $116.59M | -415175.00% | -405687.50% | -206404.23% | -137602.82% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | -754.08% | -1999.61% | -1887.55% | -2072.97% |
| BGM Group Ltd. (BGM)vs › | $118.63M | -33.18% | -17.71% | -9.45% | -4.00% |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -255.05% | -370.20% | -218.02% | -145.34% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 28.39% | 14.20% | 7.10% | 4.73% |
| Immunic, Inc. (IMUX)vs › | $109.93M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
89.2%
Operating Margin
-265.6%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -54.78% |
| 2026-03-31 | -660.33% |
| 2025-12-31 | -211.92% |
| 2025-09-30 | -226.92% |
| 2025-06-30 | -279.17% |
| 2025-03-31 | -384.96% |
| 2024-12-31 | -840.51% |
| 2024-09-30 | -305.48% |
| 2024-06-30 | -386.64% |
| 2024-03-31 | -558.30% |
| 2023-12-31 | -441.29% |
| 2023-09-30 | -97.73% |
| 2023-06-30 | -572.42% |
| 2023-03-31 | -627.56% |
| 2022-12-31 | -762.09% |
| 2022-09-30 | -425.97% |
| 2022-06-30 | -650.07% |
| 2022-03-31 | -709.29% |
| 2021-12-31 | -3938.57% |
| 2021-09-30 | -64051.22% |
| 2021-06-30 | -8337.28% |
| 2021-03-31 | -8087.41% |
| 2020-12-31 | -8278.49% |
| 2020-09-30 | -10329.05% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
